Generic Name and Formulations:
Selegiline 1.25mg; orally-disintegrating tabs; contains phenylalanine.
Valeant Pharmaceuticals, Inc
Adjunct in Parkinson's disease in patients with deteriorating response to levodopa/carbidopa.
Take (without liquids) in the AM before breakfast; do not eat/drink within 5 minutes (before or after). Place tablet on tongue, do not swallow. ≥16 yrs: 1.25mg once daily for at least 6 weeks; if needed, may increase to max 2.5mg once daily if tolerated. Do not exceed max dose. Not bioequivalent to other forms of selegiline.
<16yrs: not recommended.
During or within 2 weeks of meperidine, MAOIs (eg, other forms of selegiline). Concomitant tramadol, methadone, propoxyphene, dextromethorphan.
Renal or hepatic impairment. Monitor for melanoma. Elderly (higher risk of orthostatic hypotension). Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Avoid sympathomimetic amines, tricyclics, SSRIs, SNRIs; allow at least 14 days after discontinuing selegiline before starting an SSRI (eg, fluoxetine), tricyclic or SNRI; allow 5 weeks after discontinuing fluoxetine before starting selegiline. Caution with CYP3A4 inducers (eg, phenobarbital, phenytoin, carbamazepine, nafcillin, rifampin). Consider reducing concomitant levodopa/carbidopa dose if dyskinesia occurs.
Postural hypotension (usually transient), dizziness, GI upset, pain, headache, insomnia, rhinitis, stomatitis, hypertension, ECG abnormality, hallucinations.